+6,694.3%
MELI vs GSK
+140.0%
+6,554.3%
-89.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.6% | +0.2% | -2.8% | -2.7% |
| 7D | -6.5% | -3.6% | -2.9% | -4.4% |
| 30D | +2.8% | -5.9% | +8.8% | +6.6% |
| 3M | +14.3% | -4.3% | +18.6% | +16.4% |
| 6M | +6.0% | -10.8% | +16.8% | +12.4% |
| YTD | -6.8% | +1.8% | -8.6% | -10.0% |
| 1Y | -20.9% | +23.5% | -44.4% | -33.5% |
| 3Y | +31.4% | +49.5% | -18.2% | -8.5% |
| 5Y | -0.4% | +49.7% | -50.0% | -32.7% |
| 10Y | +951.2% | +81.9% | +869.2% | +478.0% |
| All | +6,694.3% | +140.0% | +6,554.3% | +2,799.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling